This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Administration

Authoring team

Erythropoiesis-stimulating agent (ESA) therapy:

  • should not be initiated in the presence of absolute iron deficiency without also managing the iron deficiency
  • in people with functional iron deficiency*, iron supplements should be given concurrently when initiating ESA therapy
  • when correcting anaemia of CKD, the dose and frequency of ESA should be:
    • determined by the duration of action and route of administration of the ESA
    • adjusted to keep the rate of Hb increase between 1 and 2 g/dl/month
  • ESA therapy and ACE inhibitors (or ARBs)
    • if ACE inhibitors (or ARBs) are used, an increase in ESA therapy should be considered
  • blood pressure rises transiently with administration.

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  1. NICE (September 2006). Anaemia management in people with chronic kidney disease

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.